Arterial hypertension is an important risk factor for the development of cognitive and psychoemotional disorders

In the recent years timely identification and management of cognitive and psychoemotional disorders in patients with the most common chronic non-communicable diseases has acquired special importance. Arterial hypertension (AH) is the most significant factor for the development and progression of cognitive and psychoemotional disorders. The development of AH in young and middle-aged adults is a particularly unfavourable prognostic fact. A search is currently underway for therapeutic neuroprotective strategies that can effectively prevent or reduce the damaging pathophysiological effects of hypertension on the brain. For over almost 30 years of active clinical use of the original ethylmethylhydroxypyridine succinate (EMHPS) the enormous clinical experience and evidence of therapeutic benefits in patients with various types of vascular and metabolic disorders have been accumulated. The principal pharmacological effects of EMHPS are antioxidant, antihypoxic, and membrane-protective, due to which the drug produces nootropic, anxiolytic, vegetative-stabilizing and other clinical effects. The favourable effect of EMHPS on the blood vessel wall, endothelial function and rheological properties has also been confirmed, which presents an important component of the complex therapy of a modern patient with AH. The international multicenter, randomized, double-blind and placebo-controlled study MEMO and its subanalysis showed that EMHPS is significantly effective in improving cognitive functions, anxiety and asthenia levels and patient’s quality of life during the long-term sequential therapy in patients with concomitant hypertension.

1. Drapkina OM, Kontseva AV, Kalinina AM, Avdeev SN, Agaltsov MV, Alexandrova LM et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National Guide. Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(4):3235. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3235.

2. Drapkina OM, Shishkova VN, Kotova MB. Psychoemotional risk factors for non-communicable diseases in outpatient practice. Guidelines for internists. Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(10):3438. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3438.

3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. https://doi.org/10.1097/HJH.0000000000001940.

4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. https://doi.org/10.1016/S0140-6736(21)01330-1.

5. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–223. https://doi.org/10.1016/S0140-6736(05)17741-1.

6. Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. https://doi.org/10.1097/HJH.0000000000003480.

7. Boytsov SA, Balanova YuA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention (Russian Federation). 2014;13(4):4–14. (In Russ.) https://doi.org/10.15829/1728-8800-2014-4-4-14.

8. Shishkova V.N. Place of arterial hypertension in brain lesion development – from minor cognitive disorders to dementia. Systemic Hypertension. 2014;11(1):45–51. (In Russ.) Available at: https://www.syst-hypertension.ru/jour/article/view/336.

9. Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q et al. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension. 2020;76(1):217–225. https://doi.org/10.1161/HYPERTENSIONAHA.120.14993.

10. Shishkova VN, Adasheva TV. Modern view on the mechanisms of cognitive impairment development in patients with cardiovascular diseases and the possibility of their correction. Nervous Diseases. 2021;(2):41–46. (In Russ.) https://doi.org/10.24412/2226-0757-2021-12317.

11. Teles de Menezes S, Giatti L, Brant LCC, Griep RH, Schmidt MI, Duncan BB et al. Hypertension, prehypertension, and hypertension control: association with decline in cognitive performance in the ELSA-Brasil cohort. Hypertension. 2021;77(2):672–681. https://doi.org/10.1161/HYPERTENSIONAHA.120.16080.

12. Cipollini V, Troili F, Giubilei F. Emerging Biomarkers in Vascular Cognitive Impairment and Dementia: From Pathophysiological Pathways to Clinical Application. Int J Mol Sci. 2019;20(11):2812. https://doi.org/10.3390/ijms20112812.

13. Alosco ML, Gunstad J, Beard C, Xu X, Clark US, Labbe DR et al. The synergistic effects of anxiety and cerebral hypoperfusion on cognitive dysfunction in older adults with cardiovascular disease. J Geriatr Psychiatry Neurol. 2015;28(1):57–66. https://doi.org/10.1177/0891988714541871.

14. Parfenov VA, Ostroumova TM, Ostroumova OD, Borisova EV, Perepelov VA, Perepelova EM. Cognitive functions, emotional status, MRI measurements in treatment-naive middle-aged patients with uncomplicated essential arterial hypertension. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(8):23–32. (In Russ.) https://doi.org/10.17116/jnevro201811808123.

15. Shishkova VN, Dranitsyna BG, Ustarbekova DB, Ishchuk AG, Kapustina LA. Features of neuropsychological characteristics of patients with arterial hypertension. Meditsinskiy Sovet. 2023;17(6):322–329. (In Russ.) https://doi.org/10.21518/ms2023-085.

16. Shishkova VN, Nelyubina AS, Dranitsyna BG, Kapustina LA, Ustarbekova DB. Analysis of cognitive characteristics in patients with arterial hypertension in middle and old age. Meditsinskiy Sovet. 2023;17(13):57–64. (In Russ.) https://doi.org/10.21518/ms2023-207.

17. Martynov AI, Tanashyan MM, Malyavin AG, Bogolepova AN, Borovkova NYu, Eliseeva LN et al. Resolution of the Expert Council “Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders”. Therapy. 2023;9(10):148–158. https://doi.org/10.18565/therapy.2023.10.148–158.

18. Shishkova VN. Cognitive impairments as a universal clinical syndrome in a therapist’s practice. Terapevticheskii Arkhiv. 2014;86(11):128–134. (In Russ.) Available at: https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2014/11/030040-366020141123?ysclid=lih85bemxe511367165.

19. Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B et al. Antihypertensive drugs, prevention of cognitive decline and dementia: A systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113–130. https://doi.org/10.1007/s40263-015-0230-6.

20. Ostroumova OD, Parfenov VA, Ostroumova TM, Yakhno NN, Chazova IE, Bogolepova AN et al. Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension. 2021;18(1):5–12. (In Russ.) https://doi.org/10.26442/2075082X.2021.1.200575.

21. Shishkova VN. Neuroprotection in hypertensive patients: Minimization of poor prognosis. Terapevticheskii Arkhiv. 2014;86(8):113–118. (In Russ.) Available at: https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2014/8/030040-36602014821.

22. Luca M, Luca A, Calandra C. The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer’s Disease and Vascular Dementia. Oxid Med Cell Longev. 2015;2015:504678. https://doi.org/10.1155/2015/504678.

23. Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2012;112(12):86–90. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2012/12/031997-729820121215?ysclid=m4txn0qnxu42752681.

24. Torshin IIu, Gromova OA, Sardaryan IS, Fedotova LE. A comparative chemoreactome analysis of mexidol. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(1-2):75–83. (In Russ.) https://doi.org/10.17116/jnevro20171171275-84.

25. Shetekauri SA. Modern possibilities of antioxidant therapy and experience of Mexidol treatment in patients with chronic cerebrovascular insufficiency. Bulletin of Experimental Biology and Medicine. 2006;(1):156–159. (In Russ.)

26. Tarantsova AV. Efficacy of ethylmethylhydroxypyridine succinate-based preparations. Farmateka. 2018;(5):16–25. (In Russ.) https://doi.org/10.18565/pharmateca.2018.5.16-25.

27. Pugacheva EL. Efficacy of Mexidol in patients with type 2 diabetes mellitus with neurological complications. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(5):84–89. (In Russ.) https://doi.org/10.17116/jnevro202212205184.

28. Stakhovskaya LV, Shamalov NA, Khasanova DR, Melnikova EV, Agafina AS, Golikov KV et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(3-2):55–65. (In Russ.) https://doi.org/10.17116/jnevro20171173255-65.

29. Fedin AI, Zakharov VV, Tanashyan MM, Chukanova EI, Madzhidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol forte 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(11):7–16. (In Russ.) https://doi.org/10.17116/jnevro20211211117.

30. Zakharov VV, Ostroumova OD, Kochetkov AI, Klepikova MV, Fedin AI. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Therapy. 2023;9(1):145–159. (In Russ.) https://doi.org/10.18565/therapy.2023.1.145-159.

31. Chukanova EI, Chukanova AS, Mamaeva HI. The results of the study of the efficacy and safety of mexidol in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(2):71–74. (In Russ.) https://doi.org/10.17116/jnevro20151152171-74.

32. Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(9):39–45. (In Russ.) https://doi.org/10.17116/jnevro201911909139.

33. Shchepankevich LA, Nikolaev YuA, Dolgova NA. Optimization of hypolipidemic therapy in patients with ischemic stroke and diabetes mellitus. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2016;116(2):42–45. (In Russ.) https://doi.org/10.17116/jnevro20161162142-45.

34. Kochetkov AI, Shatalova NA, Klepikova MV, Filippova TV, Ostroumova OD. More on the neuroprotectory therapy evidential base: Focus at ethylmethyl hydroxypyridine succinate. Therapy. 2023;9(8):162–172. (In Russ.) https://doi.org/10.18565/therapy.2023.8.162-172.